In conclusion, we found that NSCLC patients with a PR upon treatment with nivolumab demonstrate enhanced numbers of CD8 T cells and a phenotype corresponding with late differentiation at baseline. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.